Ventavis CoTherix, Inc. - Treatment for Pulmonary Arterial Hypertension
Ventavis is an inhaled formulation of iloprost, a prostacyclin analog, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms.Posted: December 2004
Related articles
- CoTherix, Inc. Announces Priority Review Designation by the FDA for Ventavis NDA - September 8, 2004
- CoTherix, Inc. Announces Filing of Ventavis NDA - July 1, 2004
Ventavis (iloprost) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
